"I'd like to keep an eye out for any adverse effects first," said Shi, who like many Chinese seems happy to take a wait-and-see approach.
Through aggressive lockdowns and mass testing of millions, China has had success controlling the virus that first surfaced on its soil in late 2019.
But vaccinating the world's most populous country is a different story.
China is still working to ramp up production of its four approved, domestically produced vaccines and has yet to approve any foreign-made shots in a global race for bragging rights.
For Shi, the problem is not accessibility, but a lack of urgency.
"With China's control of the epidemic domestically and my lack of plans to go abroad in the near term, there is no need for now," she said.
Chinese experts have signalled the vaccination rate could soon quicken.
Zhong Nanshan, a respected pulmonologist and key national figure in the fight against COVID-19, said recently that China planned to immunise 40 percent of its 1.4 billion people by June.
That would require massively increasing the number of jabs given in China, where currently only around 3.5 percent of the population is inoculated.
That is far behind the UK's 32.99 jabs per 100 people and the US's 25.42, according to Our World in Data, a collaboration between Oxford University and a charity.